SCHEMBL15573355

SCHEMBL15573355

CNC(=O)c1cc(Oc2ccc(CNC(=O)Nc3ccc(OC)c(Cl)c3)cc2)ccn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 4/20 0.62
RAF1 P04049 11/20 0.57
MAPK14 Q16539 5/20 0.57
BRAF P15056 4/20 0.57
EPHX2 P34913 4/20 0.57
RET P07949 4/20 0.57
KDR P35968 4/20 0.57
ABL1 P00519 3/20 0.57
EPHA2 P29317 3/20 0.57
MAP3K20 Q9NYL2 3/20 0.57
PLK4 O00444 2/20 0.57
AURKA O14965 2/20 0.57
MAPK13 O15264 2/20 0.57
MAP4K4 O95819 2/20 0.57
LCK P06239 2/20 0.57
FYN P06241 2/20 0.57
CSF1R P07333 2/20 0.57
LYN P07948 2/20 0.57
SRC P12931 2/20 0.57
RPS6KB1 P23443 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16990589 0.91 DDR2 (0.51) DDR2RAF1MAPK14BRAFEPHX2
SCHEMBL15574494 0.91 RAF1 (0.64) DDR2RAF1MAPK14BRAFEPHX2
SCHEMBL17000004 0.90 DDR2 (0.65) DDR2RAF1MAPK14BRAFEPHX2
SCHEMBL23747741 0.88 RAF1 (0.62) DDR2RAF1MAPK14BRAFEPHX2
SCHEMBL171194 0.88 DDR2 (0.67) DDR2RAF1MAPK14BRAFEPHX2
SCHEMBL171188 0.87 RAF1 (0.61) DDR2RAF1MAPK14BRAFEPHX2
SCHEMBL171306 0.86 KDR (0.58) DDR2RAF1MAPK14BRAFEPHX2
SCHEMBL171244 0.86 MAPK14 (0.58) DDR2RAF1MAPK14BRAFEPHX2
SCHEMBL16990599 0.86 NAMPT (0.59) RAF1MEN1KMT2A
SCHEMBL15574169 0.86 DDR2 (0.82) DDR2RAF1MAPK14BRAFEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US claimed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP claimed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO claimed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP disclosed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 DDR2 1/4885RAF1 3072/4885MAPK14 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.